A couple of interesting things to me. Max seems su
Post# of 154320

Two, we keep using leronlimab in advanced metastatic disease since of course those are the patients most in need of a something new. However, as Max , Dr. Pestell and Dr. Kelly have said, leronlimab maybe the key to preventing metastasis which is usually what kills in cancer.
It would need to be started earlier in the disease to do so. In a way, we are not treating the patients that might might benefit most from leronlimab which seems somewhat counterintuitive when you think about it. I realize that for the possibility of obtaining fast approval, we have to do it this way.

